Tarsus Pharmaceuticals (TARS) Cash & Current Investments (2019 - 2026)

Tarsus Pharmaceuticals' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $102.2 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 74.95% year-over-year to $102.2 million in Q1 2026; TTM through Mar 2026 was $102.2 million, a 74.95% decrease from a year earlier, with the FY2025 full-year figure at $184.2 million, down 36.78% from the prior year.
• Cash & Current Investments eased to $102.2 million in Q1 2026 per TARS's latest filing, from $184.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $407.9 million in Q1 2025 and bottomed at $102.2 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $245.4 million (2022), against an average of $260.3 million.
• Across the five-year window, Cash & Current Investments surged 81.55% in 2024 and plunged 74.95% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $217.0 million in 2022, then gained by 4.8% to $227.4 million in 2023, then climbed by 28.11% to $291.4 million in 2024, then sank by 36.78% to $184.2 million in 2025, then sank by 44.52% to $102.2 million in 2026.
• Per Business Quant, the three latest TARS Cash & Current Investments figures stand at $102.2 million (Q1 2026), $184.2 million (Q4 2025), and $401.8 million (Q3 2025).